ChiCTR2500108542 版本V1.0 版本创建时间2025/09/01 16:52:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500108542 

最近更新日期:

Date of Last Refreshed on:

2025-09-01 16:52:09 

注册时间:

Date of Registration:

2025-09-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

多模态影像学生物标志物在评估肥胖人群减重手术前后相关合并症变化中的应用:一项前瞻性纵向队列研究

Public title:

Multi-Modality Imaging Biomarkers in Evaluating Obesity-Associated Comorbidity Changes at Pre- and Post-Bariatric Surgery in an Obese Population: A Prospective and Longitudinal Cohort Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

多模态影像学生物标志物在评估肥胖人群减重手术前后相关合并症变化中的应用:一项前瞻性纵向队列研究

Scientific title:

Multi-Modality Imaging Biomarkers in Evaluating Obesity-Associated Comorbidity Changes at Pre- and Post-Bariatric Surgery in an Obese Population: A Prospective and Longitudinal Cohort Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

范金蕾 

研究负责人:

于德新 

Applicant:

Jinlei Fan 

Study leader:

Dexin Yu 

申请注册联系人电话:

Applicant telephone:

+86 152 5330 2690

研究负责人电话:

Study leader's telephone:

+86 185 6008 1629

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1213167353@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yudexin0330@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市历下区文化西路107号山东大学齐鲁医院

研究负责人通讯地址:

山东省济南市历下区文化西路107号山东大学齐鲁医院

Applicant address:

Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province

Study leader's address:

Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东大学齐鲁医院

Applicant's institution:

Qilu Hospital of Shandong University

研究负责人所在单位:

山东大学齐鲁医院

Affiliation of the Leader:

Qilu Hospital of Shandong University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYLL-202506-023-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学齐鲁医医院科研伦理委员会

Name of the ethic committee:

Qilu Medical Hospital, Shandong University Research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-08-07 00:00:00

伦理委员会联系人:

陈慧

Contact Name of the ethic committee:

Hui Chen

伦理委员会联系地址:

山东大学齐鲁医院齐鲁楼北塔12层1202办公室

Contact Address of the ethic committee:

Room 1202, 12th Floor, North Tower, Qilu Building, Qilu Hospital, Shandong University

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 531 8216 5409

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学齐鲁医院

Primary sponsor:

Qilu Hospital of Shandong University

研究实施负责(组长)单位地址:

山东省济南市历下区文化西路107号山东大学齐鲁医院

Primary sponsor's address:

Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东大学齐鲁医院

具体地址:

山东省济南市历下区文化西路107号山东大学齐鲁医院

Institution
hospital:

Qilu hospital of Shandong University

Address:

Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province

经费或物资来源:

Source(s) of funding:

None

Target disease:

Obesity

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究拟通过一项前瞻性纵向队列研究,整合多模态影像学生物标志物及临床指标,动态评估减重手术前后合并症的变化,旨在为肥胖症患者的术前精准评估和术后个体化管理提供科学依据。  

Objectives of Study:

This study aims to conduct a prospective longitudinal cohort study to integrate multimodal imaging biomarkers and clinical indicators to dynamically assess changes in comorbidities before and after weight loss surgery, with the goal of providing scientific evidence for precise preoperative assessment and individualised postoperative management of patients with obesity.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)肥胖症队列——前瞻性纳入自2025年06月至2028年06月期间于山东大学齐鲁医院减重外科进行减重手术治疗的肥胖症患者。 纳入标准: 1) 肥胖症患者(BMI≥27.5kg/m2合并肥胖症相关其他疾病,或BMI≥32.5kg/m2; 2) 年龄≥18岁; 3) 无幽闭恐惧症、无金属植入物(心脏起搏器,钢钉钢板等); 4) 无严重的心、肺、肝、肾等器官功能障碍。 (2)对照组:肝脏良性病变队列——前瞻性招募2025年06月至2028年06月期间于山东大学齐鲁医院进行手术治疗的肝脏良性病变患者。 纳入标准: 1) 年龄≥18岁; 2) 无幽闭恐惧症、无金属植入物(心脏起搏器,钢钉钢板等); 3) 无严重的心、肺、肝、肾等器官功能障碍。

Inclusion criteria

(1) Obesity Cohort — Prospective inclusion of obese patients undergoing weight-loss surgery at the Department of Bariatric Surgery, Qilu Hospital, Shandong University, from June 2025 to June 2028. Inclusion criteria: 1) Obesity patients (BMI >= 27.5 kg/m2 with obesity-related comorbidities, or BMI >= 32.5 kg/m2); 2) Age >= 18 years; 3) No claustrophobia, no metallic implants (e.g., pacemakers, metal plates, etc.); 4) No severe organ dysfunction of the heart, lungs, liver, kidneys, etc. (2) Control group: Benign liver lesion cohort — Prospective recruitment of patients with benign liver lesions undergoing surgical treatment at Shandong University Qilu Hospital from June 2025 to June 2028. Inclusion criteria: 1) Age >= 18 years; 2) No claustrophobia, no metal implants (e.g., pacemakers, steel pins, or plates); 3) No severe organ dysfunction of the heart, lungs, liver, kidneys, etc.

排除标准:

(1)肥胖症队列 排除标准: 1) 不能耐受检查或图像质量不佳; 2) 不能按时完成随访; 3) 既往肝脏恶性肿瘤病史及其他恶性肿瘤病史; 4) 既往接受过减重手术治疗。 (2)对照组 排除标准: 1) 不能耐受检查或图像质量不佳; 2) 既往肝脏恶性肿瘤病史及其他恶性肿瘤病史。

Exclusion criteria:

(1) Obesity cohort Exclusion criteria: 1) Unable to tolerate the examination or poor image quality; 2) Unable to complete follow-up on time; 3) History of liver malignancy or other malignancies; 4) Previous weight loss surgery. (2) Control Group Exclusion Criteria: 1) Unable to tolerate the examination or poor image quality; 2) History of liver malignancy or other malignant tumours.

研究实施时间:

Study execute time:

From 2025-09-01 00:00:00 To 2030-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-09-01 00:00:00 To 2028-06-30 00:00:00  

干预措施:

Interventions:

组别:

肥胖症组

样本量:

800

Group:

Obesity

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

20

Group:

Control

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

Chian 

Province:

Shandong 

City:

Jinan 

单位(医院):

山东大学齐鲁医院 

单位级别:

三甲 

Institution
hospital:

Qilu hospital of Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

CT内脏脂肪及骨骼肌面积

指标类型:

主要指标

Outcome:

CT visceral fat and skeletal muscle area

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MRI-PDFF肝脏脂肪分数

指标类型:

主要指标

Outcome:

MRI-PDFF liver fat fraction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肝脏组织

组织:

Sample Name:

liver tissue

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

脂肪组织

组织:

Sample Name:

adipose tissue

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据可在研究发表后向研究者获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data can be obtained from the researchers after the study is published.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)+电子采集和管理系统(Electronic Data Capture, EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form+Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-01 16:52:09